Partnered Evidence-Based Policy Resource Center Director Austin Frakt in a recent article published on the New York Times offers a look at some of the pros and cons of potential strategies to reduce drug pricing in the U.S. For example, Frakt writes, private insurers that drive "the hardest […]
Latest Stories
Lo Talks Drug Development, Investment
Andrew Lo with the MIT Sloan School of Management recent discussed with Evidence-Based Oncology some potential strategies to boost investment in medical innovation and utilization, the American Journal of Managed Care reports. Known for bringing to the table ideas that could bolster drug […]
Joint Investigation Finds Medical Journals Should Bolster Vetting Process
A joint investigation by ProPublica and the New York Times suggests medical journals need to focus their efforts on strengthening their vetting practices due to the number of physicians writing studies, but failing to report conflicts of interest. According to a Managed Care magazine report, the […]
Opinion: Outcomes-Based Pricing Holds Promise
Although outcomes-based pricing remains in its infancy, the Institute for Policy Innovation's Merrill Matthews writes in an article published on The Hill, it remains a promising solution to combating high drug prices. Matthews says the payment model could help address concerns about high-cost gene […]
MMIT Announces 500K-plus Physicians Use Epocrates Platform
MMIT says more than 500,000 physicians are using its formulary and restriction data in the Epocrates platform at the point of care. The platform, according to an email, offers physicians a streamlined solution that delivers quick access to "comprehensive information about drug coverage when making […]
Molina, Inovalon Partner to Offer Improved Care
Managed care service provider Molina Healthcare and Inovalon, a tech company that offers could-based platforms geared toward data-driven health care, have partnered in a bid to bolster care services with Molina's Medicaid, Medicare and marketplace members across the U.S. The partnership expands […]
Trump White House Touts International Pricing Index
The Trump administration is defending its push on a new pricing index that would look to align Medicare Part B drug prices with prices in other developed countries. In a recent blog post on the International Pricing Index proposal, Health and Human Services Senior Adviser for Drug Pricing Reform […]
Ohio Leading Push Against PBMs
Pharmacy benefit managers are facing a significant amount of scrutiny and criticism by a number of states, with Ohio being a key player after it was the first to comb through pricing data related to its two PBMs: CVS Caremark and Optum Rx. According to data collected by The Columbus Dispatch […]
Report: Generic ‘Cartel’ Probe Expands to 300 Drugs
An antitrust lawsuit levied by states in 2016 over two drugs has reportedly expanded into a full-blown investigation of alleged price-fixing of generic drugs, the Washington Post reports. Joseph Nielsen, an assistant attorney general and antitrust investigator, tells the Post the investigation […]
Deloitte: Value-Based Models Slow to Gain Momentum
The Medicare Access and CHIP Reauthorization ACT (MACRA) went into effect three years ago, and though the law offers incentives for adopting value-based models, current growth and momentum are slower than expected, according to a Deloitte blog post. "While launching pilots and tracking results have […]
